Logo image of PRGO

PERRIGO CO PLC (PRGO) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:PRGO - IE00BGH1M568 - Common Stock

15.08 USD
+0.38 (+2.59%)
Last: 1/9/2026, 8:18:21 PM
15.08 USD
0 (0%)
After Hours: 1/9/2026, 8:18:21 PM

PRGO Key Statistics, Chart & Performance

Key Statistics
Market Cap2.08B
Revenue(TTM)4.28B
Net Income(TTM)-51.80M
Shares137.62M
Float137.01M
52 Week High30.93
52 Week Low12.17
Yearly Dividend1.12
Dividend Yield8.33%
EPS(TTM)2.9
PE5.2
Fwd PE5.31
Earnings (Next)02-23 2026-02-23/amc
IPO1991-12-17
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PRGO short term performance overview.The bars show the price performance of PRGO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30 -40

PRGO long term performance overview.The bars show the price performance of PRGO in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of PRGO is 15.08 USD. In the past month the price increased by 11.54%. In the past year, price decreased by -38.15%.

PERRIGO CO PLC / PRGO Daily stock chart

PRGO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.37 1.01T
JNJ JOHNSON & JOHNSON 19.69 492.44B
MRK MERCK & CO. INC. 12.55 274.34B
PFE PFIZER INC 7.96 144.87B
BMY BRISTOL-MYERS SQUIBB CO 8.52 113.72B
ZTS ZOETIS INC 20.06 56.04B
RPRX ROYALTY PHARMA PLC- CL A 9.77 23.19B
VTRS VIATRIS INC 5.48 14.70B
ELAN ELANCO ANIMAL HEALTH INC 24.45 11.66B
AXSM AXSOME THERAPEUTICS INC N/A 8.54B
BLTE BELITE BIO INC - ADR N/A 5.53B
CRNX CRINETICS PHARMACEUTICALS IN N/A 5.05B

About PRGO

Company Profile

PRGO logo image Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company is headquartered in Dublin, Dublin and currently employs 8,379 full-time employees. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. The company primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

Company Info

PERRIGO CO PLC

The Sharp Building, Hogan Place, Dublin 2

DUBLIN DUBLIN 49010 IE

CEO: Murray S. Kessler

Employees: 8379

PRGO Company Website

PRGO Investor Relations

Phone: 3532696738451

PERRIGO CO PLC / PRGO FAQ

What does PERRIGO CO PLC do?

Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company is headquartered in Dublin, Dublin and currently employs 8,379 full-time employees. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. The company primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.


Can you provide the latest stock price for PERRIGO CO PLC?

The current stock price of PRGO is 15.08 USD. The price increased by 2.59% in the last trading session.


Does PRGO stock pay dividends?

PERRIGO CO PLC (PRGO) has a dividend yield of 8.33%. The yearly dividend amount is currently 1.12.


How is the ChartMill rating for PERRIGO CO PLC?

PRGO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Is PERRIGO CO PLC (PRGO) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRGO.


Is PERRIGO CO PLC (PRGO) expected to grow?

The Revenue of PERRIGO CO PLC (PRGO) is expected to decline by -4.18% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


How many employees does PERRIGO CO PLC have?

PERRIGO CO PLC (PRGO) currently has 8379 employees.


PRGO Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to PRGO. When comparing the yearly performance of all stocks, PRGO is a bad performer in the overall market: 90.94% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PRGO Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to PRGO. There are concerns on the financial health of PRGO while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRGO Financial Highlights

Over the last trailing twelve months PRGO reported a non-GAAP Earnings per Share(EPS) of 2.9. The EPS increased by 16.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -0.51%
ROE -1.16%
Debt/Equity 0.81
Chartmill High Growth Momentum
EPS Q2Q%-1.23%
Sales Q2Q%-4.06%
EPS 1Y (TTM)16.47%
Revenue 1Y (TTM)-2.51%

PRGO Forecast & Estimates

10 analysts have analysed PRGO and the average price target is 19.04 USD. This implies a price increase of 26.26% is expected in the next year compared to the current price of 15.08.

For the next year, analysts expect an EPS growth of 9.87% and a revenue growth -4.18% for PRGO


Analysts
Analysts76
Price Target19.04 (26.26%)
EPS Next Y9.87%
Revenue Next Year-4.18%

PRGO Ownership

Ownership
Inst Owners112.1%
Ins Owners0.45%
Short Float %10.15%
Short Ratio3.5